Physician profile
Dennis Mathews
NPI 1184617367
$7,814.75
in general payments reported to CMS, 2019-2025
30 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $577 · 2021: $1,234 · 2022: $1,034 · 2023: $1,123 · 2024: $1,356 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $873.57 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $740.38 | 2019-2022 | |
| Harrow Eye, LLC | $718.45 | 2024-2025 | Vevye |
| Abbvie INC. | $632.03 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $533.94 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $491.08 | 2019-2021 | |
| Biotissue Holdings INC. | $480.05 | 2022-2025 | |
| Allergan, INC. | $400.07 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $287.79 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $225.84 | 2019-2023 | |
| Oyster Point Pharma, INC. | $216.19 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alexion Pharmaceuticals, INC. | $211.99 | 2019 | |
| Rxsight INC | $194.11 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $178.85 | 2022-2024 | Idose |
| Shire North American Group INC | $165.55 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $160.12 | 2024-2025 | Xdemvy |
| Eyepoint US, INC. | $152.46 | 2019 | |
| Alcon Vision LLC | $152.31 | 2022-2024 | Rocklatan, Eysuvis, Argos |
| Horizon Therapeutics Plc | $144.05 | 2022-2023 | Tepezza |
| Ocular Therapeutix, INC. | $109.01 | 2023-2024 | Dextenza |
| Ivantis, INC | $104.33 | 2021 | |
| Aerie Pharmaceuticals, INC. | $103.23 | 2019-2021 | |
| Sight Sciences, INC. | $91.88 | 2022-2023 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $89.38 | 2021 | |
| Amgen INC. | $88.72 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $82.79 | 2023-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $69.67 | 2022 | |
| Eyevance Pharmaceuticals LLC | $61.92 | 2019-2022 | |
| Dompe US, INC. | $33.09 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $21.90 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.